Dyne Therapeutics (NASDAQ:DYN) Now Covered by Robert W. Baird

Stock analysts at Robert W. Baird started coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $46.00 price target on the stock. Robert W. Baird’s price objective would suggest a potential upside of 79.62% from the company’s current price.

Several other analysts have also commented on DYN. Oppenheimer restated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price objective for the company. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, Guggenheim raised their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $50.42.

Dyne Therapeutics Stock Down 6.8 %

DYN opened at $25.61 on Friday. The stock has a market cap of $2.61 billion, a PE ratio of -7.19 and a beta of 1.09. Dyne Therapeutics has a 52 week low of $10.80 and a 52 week high of $47.45. The business’s fifty day simple moving average is $30.53 and its 200 day simple moving average is $35.24.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities analysts anticipate that Dyne Therapeutics will post -3.45 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. This trade represents a 6.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Oxana Beskrovnaya sold 2,339 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the transaction, the insider now owns 140,375 shares in the company, valued at $4,849,956.25. This represents a 1.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 180,046 shares of company stock worth $6,300,265. 20.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. State of New Jersey Common Pension Fund D purchased a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $1,588,000. Seven Eight Capital LP lifted its stake in shares of Dyne Therapeutics by 195.7% during the 2nd quarter. Seven Eight Capital LP now owns 53,739 shares of the company’s stock valued at $1,896,000 after buying an additional 35,568 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of Dyne Therapeutics by 1.5% during the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after buying an additional 19,730 shares in the last quarter. Mutual of America Capital Management LLC purchased a new position in shares of Dyne Therapeutics during the 2nd quarter valued at $1,724,000. Finally, Victory Capital Management Inc. bought a new stake in Dyne Therapeutics in the 2nd quarter valued at $676,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.